ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2020
ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 643 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
643 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of ANGPTL4 in cancer: A meta-analysis of observational studies and multi-omics investigation.PloS one · 2025Pooled it
- Trial
- Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response.Gut microbes · 2026Article
- Multi-layer network biology combined with single-cell evidence reveals core regulatory nodes in atherosclerotic plaques and potential drug-targeting directions.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancer.Journal for immunotherapy of cancer · 2026Article
- Integrative analysis prioritizes proteins associated with renal cell carcinoma and its risk factors.JNCI cancer spectrum · 2026Article
- Resveratrol Modulates Lung Cancer-Associated Hub Genes Identified by Integrated Bioinformatics, Single-Cell Analysis, Molecular Docking, and Experimental Validation.Cell biochemistry and biophysics · 2026Article
- ACSL1 orchestrates ferroptosis and degranulation in low-density neutrophils: a novel pathogenic mechanism and therapeutic target in systemic lupus erythematosus.Molecular and cellular biochemistry · 2026Article
- LAMP2 drives M2 macrophage polarization and promotes glioma progression through autophagy.Discover oncology · 2026Article
- PPARα activation overcomes fibroinflammatory liver microenvironment-associated anti-PD-1 resistance in hepatocellular carcinoma by mediating GSDME-dependent pyroptosis.Nature communications · 2026Article
- Integrated Analysis of Glycolytic and Cholesterogenic Genes Identifies Prognostic Metabolic Subgroup of IDH Wild-Type Glioblastoma.Cancer medicine · 2026Article
- TBL1XR1 mutations promoted tumor progression in diffuse large B-cell lymphoma through impairing nature killer cytotoxicity via the MYC-CD47/PD-L1 axis.Molecular cancer · 2026Article
- Mucosal-associated invariant T cells promote PDAC progression via TL1A-CSF-1 axis.Journal of gastroenterology · 2026Article
- A novel mitochondrial-related gene signature for assessing the tumor immune microenvironment and predicting prognosis in human glioma.Discover oncology · 2026Article
- ImmuGT-ConRes: a consistency learning residual network for predicting pan-cancer immunotherapy response from gene expression data.NPJ precision oncology · 2026Article
- Comprehensive Bioinformatic Characterization of CD70, CD80, and TIGIT as Diagnostic, Prognostic, and Immune Biomarkers in Pan-Cancer.Current issues in molecular biology · 2026Article
- Crosstalk In: crosstalk-aware inference of tumor microenvironment cell infiltration.Journal of translational medicine · 2026Article
- Multi-omics analysis positions DNA2 at the interface of genome integrity programs and tumor behavior in pan-cancer.Functional & integrative genomics · 2026Article
- Editing regulatory network in non-small cell lung cancer: implications for immunity and metastasis.Human genomics · 2026Article
- Multi-omics and machine learning integration of diverse cell death pathways optimize risk stratification and inform drug therapy in Wilms tumor.Discover oncology · 2026Article
583 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The distribution and abundance of immune cells, particularly T-cell subsets, play pivotal roles in cancer immunology and therapy. T cells have many subsets with specific function and current methods are limited in estimating them, thus, a method for predicting comprehensive T-cell subsets is urgently needed in cancer immunology research. Here, Immune Cell Abundance Identifier (ImmuCellAI), a gene set signature-based method, is introduced for precisely estimating the abundance of 24 immune cell types including 18 T-cell subsets, from gene expression data. Performance evaluation on both the sequencing data with flow cytometry results and public expression data indicate that ImmuCellAI can estimate the abundance of immune cells with superior accuracy to other methods especially on many T-cell subsets. Application of ImmuCellAI to immunotherapy datasets reveals that the abundance of dendritic cells, cytotoxic T, and gamma delta T cells is significantly higher both in comparisons of on-treatment versus pre-treatment and responders versus non-responders. Meanwhile, an ImmuCellAI result-based model is built for predicting the immunotherapy response with high accuracy (area under curve 0.80-0.91). These results demonstrate the powerful and unique function of ImmuCellAI in tumor immune infiltration estimation and immunotherapy response prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.